Synergistic Antitumor Effects of Lovastatin and Arsenic Trioxide Combination on the MDA-MB-231 Breast Cancer Cell Line: A Drug Repositioning Approach
Jundishapur Journal of Natural Pharmaceutical Products · 30.05.2026 · 21 (2)
DOI: 10.5812/jjnpp-171667 ↗Kurz gefasst
Fachartikel in der Zeitschrift Jundishapur Journal of Natural Pharmaceutical Products, online erschienen am 30.05.2026. Verfasst von Elaheh Aghazadeh und 3 weiteren Autor:innen. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Triple-negative breast cancer (TNBC) lacks hormone- or HER2-targeted therapies and remains associated with early relapse and therapeutic resistance. Targeting metabolic pathways has emerged as a complementary approach to conventional cytotoxic therapy. The mevalonate pathway supports oncogenic signaling through prenylation-dependent activation of small GTPases, whereas arsenic trioxide (As2O3) induces oxidative stress-mediated apoptosis, thereby reducing cell viability.
Objectives
This study investigated whether pharmacologic inhibition of HMG-CoA reductase with lovastatin (Lov) enhances the cytotoxic efficacy of As2O3 in TNBC cells.
Methods
The human TNBC cell line MDA-MB-231 was treated with Lov and As2O3 as monotherapies and in combination. Cell viability was assessed using MTT assays and morphological evaluation. Long-term proliferative capacity was evaluated using clonogenic survival analysis. Drug interactions were quantified using the Chou-Talalay method, including combination index (CI) calculations and isobologram modeling.
Results
Lov and As2O3 each reduced cell viability in a concentration-dependent manner, with IC50 values of approximately 2 µM and 7.5 µM, respectively. Combined treatment produced synergistic growth inhibition across multiple concentration ratios (CI < 1), enabling significant cytotoxicity at lower drug concentrations. Clonogenic assays showed marked suppression of colony formation after combination exposure compared with single-agent treatment, indicating an impaired long-term proliferative potential.
Conclusions
Lov enhances the in vitro antitumor activity of As2O3 in MDA-MB-231 TNBC cells, supporting the potential for metabolic sensitization by targeting the mevalonate pathway. Although these findings are limited to a single cell line and require mechanistic and in vivo validation, they support further preclinical investigation of statin-based combination therapies in TNBC.
Zitieren
APA
Aghazadeh, E., Ghahremani, M. H., Ostad, S. N., & Shadboorestan, A. (2026). Synergistic Antitumor Effects of Lovastatin and Arsenic Trioxide Combination on the MDA-MB-231 Breast Cancer Cell Line: A Drug Repositioning Approach. Jundishapur Journal of Natural Pharmaceutical Products, 21(2). https://doi.org/10.5812/jjnpp-171667
Vancouver
Aghazadeh E, Ghahremani MH, Ostad SN, Shadboorestan A. Synergistic Antitumor Effects of Lovastatin and Arsenic Trioxide Combination on the MDA-MB-231 Breast Cancer Cell Line: A Drug Repositioning Approach. Jundishapur Journal of Natural Pharmaceutical Products. 2026;21(2). doi:10.5812/jjnpp-171667
BibTeX
@article{Aghazadeh2026,
author = {Aghazadeh, Elaheh and Ghahremani, Mohammad Hossein and Ostad, Seyed Nasser and Shadboorestan, Amir},
title = {Synergistic Antitumor Effects of Lovastatin and Arsenic Trioxide Combination on the MDA-MB-231 Breast Cancer Cell Line: A Drug Repositioning Approach},
journal = {Jundishapur Journal of Natural Pharmaceutical Products},
year = {2026},
volume = {21},
number = {2},
doi = {10.5812/jjnpp-171667}
}
EUVIMED